ERBB receptor feedback inhibitor 1 is a protein that in humans is encoded by the ERRFI1gene.[1][2][3][4][5]
MIG6 is a Cytoplasmicprotein whose expression is upregulated with cell growth (Wick et al., 1995). It shares significant homology with the protein product of rat gene-33, which is induced during cell stress and mediates cell signaling (Makkinje et al., 2000; Fiorentino et al., 2000).[supplied by OMIM][5]
↑Fiorini M, Ballaro C, Sala G, Falcone G, Alema S, Segatto O (Sep 2002). "Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control". Oncogene. 21 (42): 6530–6539. doi:10.1038/sj.onc.1205823. PMID12226756.
↑Benzinger, Anne; Muster Nemone; Koch Heike B; Yates John R; Hermeking Heiko (Jun 2005). "Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer". Mol. Cell. Proteomics. United States. 4 (6): 785–795. doi:10.1074/mcp.M500021-MCP200. ISSN1535-9476. PMID15778465.
Further reading
Zhang YW, Vande Woude GF (2007). "Mig-6, signal transduction, stress response and cancer". Cell Cycle. 6 (5): 507–13. doi:10.4161/cc.6.5.3928. PMID17351343.
Wick M, Bürger C, Funk M, Müller R (1995). "Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation". Exp. Cell Res. 219 (2): 527–535. doi:10.1006/excr.1995.1261. PMID7641805.
Hackel PO, Gishizky M, Ullrich A (2002). "Mig-6 is a negative regulator of the epidermal growth factor receptor signal". Biol. Chem. 382 (12): 1649–1662. doi:10.1515/BC.2001.200. PMID11843178.
Tsunoda T, Inokuchi J, Baba I, et al. (2002). "A novel mechanism of nuclear factor kappaB activation through the binding between inhibitor of nuclear factor-kappaBalpha and the processed NH(2)-terminal region of Mig-6". Cancer Res. 62 (20): 5668–71. PMID12384522.
Saarikoski ST, Rivera SP, Hankinson O (2002). "Mitogen-inducible gene 6 (MIG-6), adipophilin and tuftelin are inducible by hypoxia". FEBS Lett. 530 (1–3): 186–190. doi:10.1016/S0014-5793(02)03475-0. PMID12387890.
Anastasi S, Fiorentino L, Fiorini M, et al. (2003). "Feedback inhibition by RALT controls signal output by the ErbB network". Oncogene. 22 (27): 4221–4234. doi:10.1038/sj.onc.1206516. PMID12833145.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–45. doi:10.1038/ng1285. PMID14702039.
Xu D, Makkinje A, Kyriakis JM (2005). "Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function". J. Biol. Chem. 280 (4): 2924–2933. doi:10.1074/jbc.M408907200. PMID15556944.
Keeton AB, Messina JL (2005). "Modulation of Elk-dependent-transcription by Gene33". J. Cell. Biochem. 94 (6): 1190–1198. doi:10.1002/jcb.20370. PMID15696545.
Benzinger A, Muster N, Koch HB, et al. (2005). "Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer". Mol. Cell. Proteomics. 4 (6): 785–795. doi:10.1074/mcp.M500021-MCP200. PMID15778465.
Anastasi S, Sala G, Huiping C, et al. (2005). "Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin". Oncogene. 24 (28): 4540–4548. doi:10.1038/sj.onc.1208658. PMID15856022.
Zhang YW, Staal B, Su Y, et al. (2007). "Evidence that MIG-6 is a tumor-suppressor gene". Oncogene. 26 (2): 269–276. doi:10.1038/sj.onc.1209790. PMID16819504.